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ABSTRACT
Background: Cilostazol （CL） is an antithrombotic agent that was approved for 
prescribing under Japan’s national health insurance system in 2000. Clinical and 
experimental studies of CL to treat Alzheimer’s disease （AD） have been reported 
since 2009.
Aims: To use the propensity score method to ascertain whether CL reduced medical 
expenses among patients with AD in a prefecture of Japan.
Methods: Records of 21,181 patients with AD （6,484 males and 14,697 females） from 
April 2010 to March 2011 were selected from a claims database of the National 
Health Insurance and the Long-term Care Insurance systems in a prefecture in 
Japan. Covariates were patient characteristics, comorbidities, and drugs prescribed 
for AD, i.e. psychoactive agents, narcotics, anticonvulsants, or cholinesterase 
inhibitors. The outcome variable was medical expenses for the whole year. 
Results: The propensity score indicated that patients receiving CL had medical 
expenses ￥10.9 higher than those of patients not receiving CL.
Conclusion: According to the propensity score method, CL did not efficiently reduce 
medical expenses for patients with AD based on claims data.
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Background
Alzheimer’s disease （AD） is a chronic progressive neurodegenerative disease （1-3） that poses a 
severe socioeconomic burden （4-6）．Cilostazol （CL） is an antithrombotic agent （7, 8） that has become 
available under Japan’s National Health Insurance system since 2000. CL is reported to prevent 
pathological changes of AD in experimental animal models （9, 10）．Clinical use of CL to treat AD was 
first reported in 2009 （11）， and subsequent studies have been reported （12-13, 16）．CL was occasionally 
prescribed to patients with AD for its antithrombotic effect since CL was not approved for 
prescription to patients with AD at the time. Therefore, one could assume that CL was prescribed to 
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patients with AD in a seemingly random manner, representing a “natural experiment” （14）．If CD 
was clinically effective in treating AD, then it should reduce medical expenses for patients.
A propensity score is the probability that a unit will be assigned to a particular treatment given a 
set of observed covariates, and it is used to reduce selection bias by equating groups based on 
covariates. 
A search revealed no studies of medical expenses for CL to treat AD. Therefore, the propensity 
score method was used to analyze medical expenses for CL to treat AD.
Aims
The aim of this study was to use the propensity score method to ascertain whether CL reduced 
medical expenses among patients with Alzheimer’s disease in a prefecture of Japan
Methods
Records of 21,181 patients with AD （6,484 males and 14,697 females） from April 2010 to March 
2011 in a prefecture in Japan were selected from a claims database of the National Health Insurance 
and the Long-term Care Insurance systems （Figure 1）．The characteristics of the prefecture were 
as described in a previous study （15）．Covariates were patient characteristics （age, sex, address）， 
comorbidities, and drugs prescribed for AD, i.e. psychoactive agents, narcotics, anticonvulsants, or 
cholinesterase inhibitors （Table 1）．
The outcome variable was medical expenses （log-transformed） for the whole year （Table 2）．The 
propensity score method was used to compare patients who were prescribed CL and patients who 
were not prescribed CL. Comparison was performed using the open-source statistical software R 
（version 3.3.2）．
Figure 1．Flow chart of the study
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Results
The profile of both groups of patients is shown in Table 1. Patient characteristics, comorbidities, 
and prescribed drugs differed markedly. Patients receiving CL had higher medical expenses than 
patients not receiving CL （Table 1）．
The receiver operating characteristic （ROC） curve is shown in Figure 2, and the C-statistic was 
0.7484 （95%CI 0.74‒0.7569）．The distribution of the 2 groups is shown in Figure 3. The distribution 
indicated that data were amenable for analysis using the propensity score method.
The propensity score indicated that medical expenses for patients receiving CL were ￥10.9 
higher than those of patients not receiving CL, and this difference was significant （Table 2）．
Discussion
The propensity score indicated that medical expenses for patients receiving CL were only 1 yen 
higher than those for patients not receiving CL, although this difference was significant. The 
difference was so small that one could not confidently claim that CL reduced medical expenses for 
patients with AD.
Experimentally, CL has been tested in mice that received central injections with amyloid beta. 
Repeated administration of CL reduced the accumulation of amyloid beta and tau phosphorylation （9） 
and improved cognitive performance in several behavioral paradigms （10）．
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In 2009, Arai et al. first reported administering 100 mg of CL per day as an add-on to donepezil to 
10 patients with mild to moderate AD （11）．A subsequent study examined the effect of CL on 
cognition and regional cerebral blood flow in elderly patients with AD and cerebrovascular disease 
over a period of 6 months （16）， but patients receiving CL exhibited no change in cognitive function as 
reflected in their test scores, whereas the control group exhibited a cognitive decline on the 
Alzheimer’s Disease Assessment Scale-Cognitive subscale. When healthy subjects were acutely 
Table 1．profile of cilostazol （+） group and cilostazol （-） group
Table 2．results of propensity score method
 estimate 
std. 
error 
t-value p-value
medical cost   ¥ 10.9 10.2 3.84 0.0001
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Figure 2．ROC and c-statistics
ROC curve showed adequate separation of two groups as C-statistics was 0.7484 95% CI 0.7400-0.7569）．The 
C-statistics was acceptable for the propensity score method.
Figure 3．distribution of propensity score
The two groups had clearly different shapes.
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treated, an increase in cerebral blood flow was not noted. A later study compared the effects of CL 
and donepezil and donepezil alone on subcortical white matter hyperintensities in patients with mild 
to moderate AD. Patients receiving CL and donepezil or donepezil alone did not differ in cognitive 
measures, which included the Mini-Mental State Examination （MMSE） and the Cognitive subscale 
of the Alzheimer’s Disease Assessment Scale. A recent case-control study examined 60 patients with 
stable AD receiving acetylcholinesterase inhibitors; patients were equally divided into a placebo 
group and a group receiving CL as an add-on therapy for at least 12 months. CL was found to 
improve the MMSE score and the Clinical Dementia Rating sum of boxes scores of patients with AD 
already receiving acetylcholinesterase inhibitors （17）．
In addition, two retrospective studies reported that average doses of CL for 6 months alleviated 
mild cognitive impairment according to the MMSE score （18, 19）．These clinical studies seem to 
indicate that CL might improve cognition, and particularly in patients with mild cognitive 
impairment and mild AD （13）．A randomized control trial of CL in treating mild cognitive impairment 
is reported to be underway （20）．
An economic evaluation of using CL to treat AD is needed to reduce the economic burden of care 
for AD （1, 2）．
Limitations
The current study had several limitations. The first is that this study was an observational study 
and not a randomized control trial. 
The second limitation is that data on claims in one prefecture were selected from a database of 
the National Health Insurance and the Long-term Care Insurance systems. The prefecture had an 
average profile among the 47 prefectures in Japan （15）．Presumably, the current results could be 
generalized to Japan as a whole. 
The third limitation is that psychoactive agents and narcotics served as covariates to control for 
confounders. However, the propensity score method is not able to control for unmeasured 
confounders. Thus, uncontrolled confounders may exist. 
Conclusion
According to the propensity score method, CL did not efficiently reduce medical expenses for 
patients with AD based on claims data.
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